ORMD-0901

ORMD-0901 is an **oral formulation of exenatide**, a glucagon-like peptide-1 (GLP-1) analog. Exenatide is a synthetic peptide that mimics the incretin hormone GLP-1, which stimulates insulin secretion from the pancreas in a glucose-dependent manner, inhibits glucagon secretion, slows gastric emptying, and induces satiety. Unlike traditional exenatide therapies, which are only available via injection, ORMD-0901 utilizes proprietary oral delivery technology to enable gastrointestinal absorption and preserve peptide activity. The drug is being developed primarily for the treatment of type 2 diabetes, with the aim of improving patient compliance through oral administration. Early clinical studies have shown that oral ORMD-0901 is well tolerated and reduces postprandial glucose excursions in both animal models and humans, demonstrating pharmacodynamic activity similar to injectable exenatide[1][2][3][5][7][9].

Other names

exenatide oraloral GLP-1 analog capsule